Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LXEO Stock Forecast 2026-2027
$6.53
Current Price
$511.94M
Market Cap
Buy 11
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LXEO Price Targets
+359.4%
To High Target of $30.00
+191.0%
To Median Target of $19.00
+53.1%
To Low Target of $10.00
LXEO Price Momentum
-2.1%
1 Week Change
+15.6%
1 Month Change
+103.4%
1 Year Change
-34.2%
Year-to-Date Change
-40.6%
From 52W High of $10.99
+168.7%
From 52W Low of $2.43
📊 TOP ANALYST CALLS
Did LXEO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lexeo is one of their latest high-conviction picks.
Latest LXEO Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, LXEO has a bullish consensus with a median price target of $19.00 (ranging from $10.00 to $30.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $6.53, the median forecast implies a 191.0% upside. This outlook is supported by 11 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Debjit Chattopadhyay at Guggenheim, projecting a 359.4% upside. Conversely, the most conservative target is provided by Mitchell S. Kapoor at HC Wainwright & Co., suggesting a 53.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LXEO Analyst Ratings
11
Buy
0
Hold
0
Sell
LXEO Price Target Range
Low
$10.00
Average
$19.00
High
$30.00
Current: $6.53
Latest LXEO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LXEO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 13, 2026 | Chardan Capital | Geulah Livshits | Buy | Maintains | $17.00 |
| Jan 13, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $10.00 |
| Dec 18, 2025 | Raymond James | Christopher Raymond | Strong Buy | Initiates | $25.00 |
| Dec 11, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $17.00 |
| Dec 1, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Initiates | $19.00 |
| Nov 20, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Initiates | $19.00 |
| Nov 6, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 5, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $17.00 |
| Oct 21, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $13.00 |
| Oct 15, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Initiates | $30.00 |
| Oct 7, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $17.00 |
| Oct 7, 2025 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $20.00 |
| Oct 7, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $15.00 |
| Aug 15, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $9.00 |
| Aug 15, 2025 | Leerink Partners | Outperform | Maintains | $N/A | |
| Aug 15, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| Jul 31, 2025 | Oppenheimer | Leland Gershell | Outperform | Initiates | $20.00 |
| May 30, 2025 | JP Morgan | Tessa Romero | Overweight | Maintains | $10.00 |
| May 16, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $15.00 |
| May 13, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $20.00 |
Lexeo Therapeutics Inc. (LXEO) Competitors
The following stocks are similar to Lexeo based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lexeo Therapeutics Inc. (LXEO) Financial Data
Valuation Metrics
Market Cap
$511.94M
Enterprise Value
$338.06M
P/E Ratio
N/A
PEG Ratio
-5.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+37.6%
Current Ratio
11.2x
Debt/Equity
3.2x
ROE
-55.0%
ROA
-32.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lexeo Therapeutics Inc. (LXEO) Business Model
About Lexeo Therapeutics Inc.
What They Do
Develops innovative genetic therapies for complex diseases.
Business Model
Lexeo Therapeutics generates revenue by developing and commercializing genetic therapies aimed at treating complex genetic disorders. The company focuses on specific areas such as cardiology, ophthalmology, and neurodegenerative diseases, utilizing advanced gene therapy technologies to provide targeted and effective treatment options.
Additional Information
Lexeo Therapeutics is positioned in the biotechnology sector as a pioneer in precision medicine, aiming to correct or replace defective genes. This innovative approach not only enhances patient outcomes but also plays a significant role in the future of genetic medicine and biopharmaceutical innovation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
59
CEO
Mr. R. Nolan Townsend M.B.A.
Country
United States
IPO Year
N/A
Website
www.lexeotx.comLexeo Therapeutics Inc. (LXEO) Latest News & Analysis
Latest News
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
21 days ago
Quick Summary
Lexeo Therapeutics submitted protocols for its LX2006 trial to the FDA, with study initiation expected in H1 2026. The company has $246.6 million in cash, providing runway into 2028.
Why It Matters
Lexeo Therapeutics' trial progress, strong financial position, and strategic collaborations suggest potential for growth in the genetic medicine sector, impacting investor sentiment positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026, at 10:00 a.m. ET in Miami, FL.
Why It Matters
Lexeo Therapeutics' participation in a major healthcare conference may signal potential investor interest and insights into its innovative treatments, impacting stock performance and market sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
2 months ago
Quick Summary
Lexeo Therapeutics, Inc. (LXEO) presented at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026, highlighting its strategic developments and future plans in the biotechnology sector.
Why It Matters
Lexeo Therapeutics' presentation at a prominent biotech summit signals potential growth opportunities and investor interest, impacting stock performance and market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 with a fireside chat on February 12, 2026, at 12:30 p.m.
Why It Matters
Lexeo Therapeutics' participation in key investor conferences highlights its strategic engagement with the investment community, potentially influencing stock interest and valuation in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lexeo Therapeutics (Nasdaq: LXEO) appointed new senior leadership to enhance expertise in cardiovascular medicine and updated on its partnership with Perceptive Xontogeny and venBio to develop genetic cardiac therapies.
Why It Matters
Leadership changes at Lexeo Therapeutics signal a strengthened focus on cardiovascular medicine, potentially boosting innovation and investor confidence in upcoming genetic therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
3 months ago
Quick Summary
Lexeo Therapeutics, Inc. (LXEO) presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting key developments and strategic initiatives.
Why It Matters
Lexeo Therapeutics' presentation at a major healthcare conference could indicate potential growth opportunities or partnerships, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About LXEO Stock
What is Lexeo Therapeutics Inc.'s (LXEO) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Lexeo Therapeutics Inc. (LXEO) has a median price target of $19.00. The highest price target is $30.00 and the lowest is $10.00.
Is LXEO stock a good investment in 2026?
According to current analyst ratings, LXEO has 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LXEO stock?
Wall Street analysts predict LXEO stock could reach $19.00 in the next 12 months. This represents a 191.0% increase from the current price of $6.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lexeo Therapeutics Inc.'s business model?
Lexeo Therapeutics generates revenue by developing and commercializing genetic therapies aimed at treating complex genetic disorders. The company focuses on specific areas such as cardiology, ophthalmology, and neurodegenerative diseases, utilizing advanced gene therapy technologies to provide targeted and effective treatment options.
What is the highest forecasted price for LXEO Lexeo Therapeutics Inc.?
The highest price target for LXEO is $30.00 from Debjit Chattopadhyay at Guggenheim, which represents a 359.4% increase from the current price of $6.53.
What is the lowest forecasted price for LXEO Lexeo Therapeutics Inc.?
The lowest price target for LXEO is $10.00 from Mitchell S. Kapoor at HC Wainwright & Co., which represents a 53.1% increase from the current price of $6.53.
What is the overall LXEO consensus from analysts for Lexeo Therapeutics Inc.?
The overall analyst consensus for LXEO is bullish. Out of 13 Wall Street analysts, 11 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $19.00.
How accurate are LXEO stock price projections?
Stock price projections, including those for Lexeo Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 3:13 AM UTC